Show simple item record

dc.contributor.authorCapdevila, J
dc.contributor.authorFazio, N
dc.contributor.authorLopez, C
dc.contributor.authorTeule, A
dc.contributor.authorValle, Juan W
dc.contributor.authorTafuto, S
dc.contributor.authorCustodio, A
dc.contributor.authorReed, N
dc.contributor.authorRaderer, M
dc.contributor.authorGrande, E
dc.contributor.authorGarcia-Carbonero, R
dc.contributor.authorFonseca, P
dc.contributor.authorAlonso, V
dc.contributor.authorAntonuzzo, L
dc.contributor.authorSpallanzani, A
dc.contributor.authorBerruti, A
dc.contributor.authorGarcia, I
dc.contributor.authorLa, Casta A
dc.contributor.authorHernando, J
dc.contributor.authorIbrahim, T
dc.date.accessioned2019-04-29T09:49:02Z
dc.date.available2019-04-29T09:49:02Z
dc.date.issued2018en
dc.identifier.citationCapdevila J, Fazio N, Lopez C, Teule A, Valle JW, Tafuto S, et al. 1307OEfficacy of lenvatinib in patients with advanced pancreatic (panNETs) and gastrointestinal (giNETs) grade 1/2 (G1/G2) neuroendocrine tumors: results of the international phase II TALENT trial (GETNE 1509). Ann Oncol. 2018;29(suppl_8):467.en
dc.identifier.doi10.1093/annonc/mdy293en
dc.identifier.urihttp://hdl.handle.net/10541/621809
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1093/annonc/mdy293en
dc.titleEfficacy of lenvatinib in patients with advanced pancreatic (panNETs) and gastrointestinal (giNETs) grade 1/2 (G1/G2) neuroendocrine tumors: results of the international phase II TALENT trial (GETNE 1509)en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentGastrointestinal and Endocrine Tumor Unit, Vall d'Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO) Barcelona, Spainen
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record